Literature DB >> 19223644

Human immunodeficiency virus type 1 isolates with the reverse transcriptase (RT) mutation Q145M retain nucleoside and nonnucleoside RT inhibitor susceptibility.

Vici Varghese1, Yumi Mitsuya, Rajin Shahriar, Michael H Bachmann, W Jeffrey Fessel, Ron M Kagan, Robert W Shafer.   

Abstract

Q145M, a mutation in a conserved human immunodeficiency virus type 1 reverse transcriptase (RT) region, was reported to decrease susceptibility to multiple RT inhibitors. We report that Q145M and other Q145 mutations do not emerge with RT inhibitors nor decrease RT inhibitor susceptibility. Q145M should not, therefore, be considered an RT inhibitor resistance mutation.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19223644      PMCID: PMC2681550          DOI: 10.1128/AAC.01593-08

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  10 in total

1.  Detection of a new HIV-1 reverse transcriptase mutation (Q145M) conferring resistance to nucleoside and non-nucleoside inhibitors in a patient failing highly active antiretroviral therapy.

Authors:  Stefania Paolucci; Fausto Baldanti; Marco Tinelli; Giovanni Maga; Giuseppe Gerna
Journal:  AIDS       Date:  2003-04-11       Impact factor: 4.177

2.  Comparison of the precision and sensitivity of the Antivirogram and PhenoSense HIV drug susceptibility assays.

Authors:  Jie Zhang; Soo-Yon Rhee; Jonathan Taylor; Robert W Shafer
Journal:  J Acquir Immune Defic Syndr       Date:  2005-04-01       Impact factor: 3.731

3.  Panel of prototypical infectious molecular HIV-1 clones containing multiple nucleoside reverse transcriptase inhibitor resistance mutations.

Authors:  Elizabeth Johnston; Kathryn M Dupnik; Matthew J Gonzales; Mark A Winters; Soo-Yon Rhee; Tomozumi Imamichi; Robert W Shafer
Journal:  AIDS       Date:  2005-04-29       Impact factor: 4.177

Review 4.  HIV-1 protease and reverse transcriptase mutations for drug resistance surveillance.

Authors:  Robert W Shafer; Soo-Yon Rhee; Deenan Pillay; Veronica Miller; Paul Sandstrom; Jonathan M Schapiro; Daniel R Kuritzkes; Diane Bennett
Journal:  AIDS       Date:  2007-01-11       Impact factor: 4.177

Review 5.  HIV-1 drug resistance mutations: an updated framework for the second decade of HAART.

Authors:  Robert W Shafer; Jonathan M Schapiro
Journal:  AIDS Rev       Date:  2008 Apr-Jun       Impact factor: 2.500

6.  A novel phenotypic drug susceptibility assay for human immunodeficiency virus type 1.

Authors:  C J Petropoulos; N T Parkin; K L Limoli; Y S Lie; T Wrin; W Huang; H Tian; D Smith; G A Winslow; D J Capon; J M Whitcomb
Journal:  Antimicrob Agents Chemother       Date:  2000-04       Impact factor: 5.191

7.  Gln145Met/Leu changes in human immunodeficiency virus type 1 reverse transcriptase confer resistance to nucleoside and nonnucleoside analogs and impair virus replication.

Authors:  Stefania Paolucci; Fausto Baldanti; Giovanni Maga; Reynel Cancio; Maurizio Zazzi; Maurizio Zavattoni; Antonella Chiesa; Silvio Spadari; Giuseppe Gerna
Journal:  Antimicrob Agents Chemother       Date:  2004-12       Impact factor: 5.191

8.  Comparative analysis of two commercial phenotypic assays for drug susceptibility testing of human immunodeficiency virus type 1.

Authors:  Shoukat H Qari; Richard Respess; Hillard Weinstock; Elise M Beltrami; Kurt Hertogs; Brendan A Larder; Christos J Petropoulos; Nicholas Hellmann; Walid Heneine
Journal:  J Clin Microbiol       Date:  2002-01       Impact factor: 5.948

9.  A rapid method for simultaneous detection of phenotypic resistance to inhibitors of protease and reverse transcriptase in recombinant human immunodeficiency virus type 1 isolates from patients treated with antiretroviral drugs.

Authors:  K Hertogs; M P de Béthune; V Miller; T Ivens; P Schel; A Van Cauwenberge; C Van Den Eynde; V Van Gerwen; H Azijn; M Van Houtte; F Peeters; S Staszewski; M Conant; S Bloor; S Kemp; B Larder; R Pauwels
Journal:  Antimicrob Agents Chemother       Date:  1998-02       Impact factor: 5.191

10.  Structure of a covalently trapped catalytic complex of HIV-1 reverse transcriptase: implications for drug resistance.

Authors:  H Huang; R Chopra; G L Verdine; S C Harrison
Journal:  Science       Date:  1998-11-27       Impact factor: 47.728

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.